123 related articles for article (PubMed ID: 20167483)
1. Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists.
He S; Dobbelaar PH; Liu J; Jian T; Sebhat IK; Lin LS; Goodman A; Guo C; Guzzo PR; Hadden M; Henderson AJ; Ruenz M; Sargent BJ; Yet L; Kelly TM; Palyha O; Kan Y; Pan J; Chen H; Marsh DJ; Shearman LP; Strack AM; Metzger JM; Feighner SD; Tan C; Howard AD; Tamvakopoulos C; Peng Q; Guan XM; Reitman ML; Patchett AA; Wyvratt MJ; Nargund RP
Bioorg Med Chem Lett; 2010 Mar; 20(6):1913-7. PubMed ID: 20167483
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR of heterocyclic carboxylic acid isosteres based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.
Hadden M; Goodman A; Guo C; Guzzo PR; Henderson AJ; Pattamana K; Ruenz M; Sargent BJ; Swenson B; Yet L; Liu J; He S; Sebhat IK; Lin LS; Tamvakopoulos C; Peng Q; Kan Y; Palyha O; Kelly TM; Guan XM; Metzger JM; Reitman ML; Nargund RP
Bioorg Med Chem Lett; 2010 May; 20(9):2912-5. PubMed ID: 20347296
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.
Liu J; He S; Jian T; Dobbelaar PH; Sebhat IK; Lin LS; Goodman A; Guo C; Guzzo PR; Hadden M; Henderson AJ; Pattamana K; Ruenz M; Sargent BJ; Swenson B; Yet L; Tamvakopoulos C; Peng Q; Pan J; Kan Y; Palyha O; Kelly TM; Guan XM; Howard AD; Marsh DJ; Metzger JM; Reitman ML; Wyvratt MJ; Nargund RP
Bioorg Med Chem Lett; 2010 Apr; 20(7):2074-7. PubMed ID: 20219372
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists.
Guo C; Guzzo PR; Hadden M; Sargent BJ; Yet L; Kan Y; Palyha O; Kelly TM; Guan X; Rosko K; Gagen K; Metzger JM; Dragovic J; Lyons K; Lin LS; Nargund RP
Bioorg Med Chem Lett; 2010 May; 20(9):2785-9. PubMed ID: 20371178
[TBL] [Abstract][Full Text] [Related]
5. Pyridinesulfonylureas and pyridinesulfonamides as selective bombesin receptor subtype-3 (BRS-3) agonists.
Lo MM; Chobanian HR; Palyha O; Kan Y; Kelly TM; Guan XM; Reitman ML; Dragovic J; Lyons KA; Nargund RP; Lin LS
Bioorg Med Chem Lett; 2011 Apr; 21(7):2040-3. PubMed ID: 21354793
[TBL] [Abstract][Full Text] [Related]
6. Discovery of high affinity bombesin receptor subtype 3 agonists.
Wu JM; Nitecki DE; Biancalana S; Feldman RI
Mol Pharmacol; 1996 Nov; 50(5):1355-63. PubMed ID: 8913368
[TBL] [Abstract][Full Text] [Related]
7. Systematic optimization of a lead-structure identities for a selective short peptide agonist for the human orphan receptor BRS-3.
Weber D; Berger C; Heinrich T; Eickelmann P; Antel J; Kessler H
J Pept Sci; 2002 Aug; 8(8):461-75. PubMed ID: 12212809
[TBL] [Abstract][Full Text] [Related]
8. Discovery of small molecule agonists for the bombesin receptor subtype 3 (BRS-3) based on an omeprazole lead.
Carlton DL; Collin-Smith LJ; Daniels AJ; Deaton DN; Goetz AS; Laudeman CP; Littleton TR; Musso DL; Morgan RJ; Szewczyk JR; Zhang C
Bioorg Med Chem Lett; 2008 Oct; 18(20):5451-5. PubMed ID: 18818070
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent and selective peptide agonists at the GRP-preferring bombesin receptor (BB2).
Darker JG; Brough SJ; Heath J; Smart D
J Pept Sci; 2001 Nov; 7(11):598-605. PubMed ID: 11763364
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel chiral diazepines as bombesin receptor subtype-3 (BRS-3) agonists with low brain penetration.
Matsufuji T; Shimada K; Kobayashi S; Kawamura A; Fujimoto T; Arita T; Hara T; Konishi M; Abe-Ohya R; Izumi M; Sogawa Y; Nagai Y; Yoshida K; Takahashi H
Bioorg Med Chem Lett; 2014 Feb; 24(3):750-5. PubMed ID: 24412111
[TBL] [Abstract][Full Text] [Related]
11. Discovery of imidazole carboxamides as potent and selective CCK1R agonists.
Zhu C; Hansen AR; Bateman T; Chen Z; Holt TG; Hubert JA; Karanam BV; Lee SJ; Pan J; Qian S; Reddy VB; Reitman ML; Strack AM; Tong V; Weingarth DT; Wolff MS; MacNeil DJ; Weber AE; Duffy JL; Edmondson SD
Bioorg Med Chem Lett; 2008 Aug; 18(15):4393-6. PubMed ID: 18614364
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists.
Gore VK; Ma VV; Tamir R; Gavva NR; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2007 Nov; 17(21):5825-30. PubMed ID: 17851073
[TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
14. Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
Paone DV; Nguyen DN; Shaw AW; Burgey CS; Potteiger CM; Deng JZ; Mosser SD; Salvatore CA; Yu S; Roller S; Kane SA; Selnick HG; Vacca JP; Williams TM
Bioorg Med Chem Lett; 2011 May; 21(9):2683-6. PubMed ID: 21251825
[TBL] [Abstract][Full Text] [Related]
15. The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerization.
Chobanian HR; Guo Y; Liu P; Lanza TJ; Chioda M; Chang L; Kelly TM; Kan Y; Palyha O; Guan XM; Marsh DJ; Metzger JM; Raustad K; Wang SP; Strack AM; Gorski JN; Miller R; Pang J; Lyons K; Dragovic J; Ning JG; Schafer WA; Welch CJ; Gong X; Gao YD; Hornak V; Reitman ML; Nargund RP; Lin LS
Bioorg Med Chem; 2012 May; 20(9):2845-9. PubMed ID: 22494842
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent, orally bioavailable small-molecule inhibitors of the human CCR2 receptor.
Doyon J; Coesemans E; Boeckx S; Buntinx M; Hermans B; Van Wauwe JP; Gilissen RA; De Groot AH; Corens D; Van Lommen G
ChemMedChem; 2008 Apr; 3(4):660-9. PubMed ID: 18188859
[TBL] [Abstract][Full Text] [Related]
17. Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists.
Baxter A; Cooper A; Kinchin E; Moakes K; Unitt J; Wallace A
Bioorg Med Chem Lett; 2006 Feb; 16(4):960-3. PubMed ID: 16297626
[TBL] [Abstract][Full Text] [Related]
18. Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety.
Russell MG; Carling RW; Street LJ; Hallett DJ; Goodacre S; Mezzogori E; Reader M; Cook SM; Bromidge FA; Newman R; Smith AJ; Wafford KA; Marshall GR; Reynolds DS; Dias R; Ferris P; Stanley J; Lincoln R; Tye SJ; Sheppard WF; Sohal B; Pike A; Dominguez M; Atack JR; Castro JL
J Med Chem; 2006 Feb; 49(4):1235-8. PubMed ID: 16480260
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor.
Lin NH; Wang L; Wang X; Wang GT; Cohen J; Gu WZ; Zhang H; Rosenberg SH; Sham HL
Bioorg Med Chem Lett; 2004 Oct; 14(20):5057-62. PubMed ID: 15380198
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
